TD Cowen Maintains Buy on Tandem Diabetes Care, Raises Price Target to $28

Benzinga Newsdesk www.benzinga.com Positive 78.6%

Neg 0% Neu 0% Pos 78.6%

TD Cowen analyst Mathew Blackman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and raises the price target from $25 to $28.